What a difference a week makes for biotech stocks
Last week the biotech sector seemed in freewill. Bristol Myers Squibb (BMY) had made a deal to buy Celgene (CELG) at a whopping 54% premium to Wednesday’s close and the sector dropped on the news. The prevailing theory was that the deal removed one hungry big...
Adding yen exposure to Jubak Picks and Volatility Portfolios
On December 27 I switched to the Invesco Currency Shares Japanese Yen ETF (FXY) from the Vanguard FTSE Developed Markets ETF (VEA) in my Perfect 5 ETF Portfolio (on my subscription sites JugglingWithKnives.com and JubakAM.com) in an effort to get more yen exposure...
Pulling the plug on any significant end of the year rally: Selling small cap Russell 2000 ETF
Going into December, I thought there was enough chance of a strong end of the year rally/ January effect rally to make taking a risk on small company stocks a reasonable call. Even though the entire market looked shaky in the longer term. (That is in 2019.) With the...
My second global warming pick is Jubak Picks member Xylem
Xylem (XYL) One of the “ironies” (for lack of a better word) of Global Warming is that it will put lots of water where many people don’t want it, and it will leave many regions that have enough water now thirsty, and it will threaten to turn many existing supplies of...
Oil gains on Trump-Xi “success, Russia-Saudi “deal,” and actual production cuts from Alberta
As of 2:30 p.m. New York time U.S. benchmark West Texas Intermediate was up 3.04% to $52.48 a barrel. International benchmark Brent crude gained 2.84% to break back above $60 a barrel at $61.15. Part of the reason for the gain is a general sigh of relief that the...
Incyte knocking on the door of a new upward trend after today’s 6% pop
Reports of results from the December 1-4 meeting of the American Society of Hematology continue to move biotech stocks. Today it was Incyte’s (INCY) turn. The company announced positive results for a Phase 2 trial evaluating Incyte’s Jakafi in combination...
Jubak Picks member Salesforce beats on earnings, raises guidance for 2019 and 2020
Salesforce (CRM) started today to the upside based on last night’s earnings beat of 11 cents a share. Salesforce shares were up 4.57% as of noon New York time today. And then came the market-wide bounce after Fed chair Jerome Powell’s speech suggesting...
Ionis Pharmaceuticals showing strong recovery on research pipeline, tweaking price target higher
It’s been a wild 2018 for Jubak Picks portfolio stock Ionis Pharmaceuticals (IONS.) Right now, though, the shares are on an upward trend. That’s likely to continue with the company looking at a strong research presentation at the December 1-4 meeting of...
Mixed news in Alibaba’s new Singles’ Day sales record
The 10th annual Singles’ Day sales frenzy on November 11 resulted in a new record at China’s Alibaba (BABA) for one-day sales of $213.5 billion yuan ($30.7 billion.) This year merchandise sales for the world’s largest off-line and on-line shopping...
Buying shares of small caps ETF for my Jubak Picks Portfolio today
In my Special Report “How to Protect Our Portfolio Without Selling Your Portfolio” (available to subscribers to my JubakAM.com site) I made the iShares Russell 2000 ETF (IWM) my third Portfolio Protection Pick. Today I’m adding it to my Jubak Picks...
Buy Salesforce My Newest Big Thing Stock for Jubak Picks Portfolio
My apologies that I didn’t get this post up last night but I had a short, strange, and very scary attack of vertigo at the end of my working day and missed that deadline. Everything seems to be fine today so here’s the post. When I added Salesforce.com...
Autoliv shares move up as future outweighs past
Before the market open today, Autoliv (ALV) delivered disappointing earnings for the third quarter. But the stock still climbed on news that China is considering cutting the tax on car purchases to 5% from 10% in an effort to stimulate the country’s auto market...
Incyte news continues to rebuild credibility of pipeline
Shares of Incyte (INCY) climbed 2.51% today on the announcement of positive results from a Phase 2 clinical trial, GEOMETRY mono-1, evaluating MET inhibitor capmatinib in 94 adult patients with advanced non-small cell lung cancer. The company presented the data at...
Oil sells off as Hurricane Michael goes from “rumor” to “fact”
Today’s drop in oil prices looks to me to be a classic buy on the rumor sell on the fact trade. U.S. benchmark West Texas Intermediate dropped 2.81% today to $72.85. International benchmark Brent crude fell 2.68% to $82.72 a barrel. Yesterday oil moved up as...
Oil moves higher today on Hurricane Michael, IEA supply warning
U.S. benchmark West Texas Intermediate crude climbed 0.7% today to close at $74.81 a barrel. International benchmark Brent crude rose 1.23% to $84.94 a barrel. The International Energy Agency warned of what it termed a “risky situation; the oil markets are...
Why Nektar is extremely oversold right now
The longs and the shorts continue to battle over Nektar Therapeutics (NKTR.) Right now the shorts have the best of that fight. No contest. The shares of this biotech fell another 1.24% today to close at $51.71. A little more than a month ago they were at $68.49. But I...
Lions Gate Entertainment climbs again on Tuesday, October 2
Investors and traders are sure acting like they believe the Hollywood studio will be an acquisition target–soon–by one of the companies engaged in the heated battle to gain traction in the market for streaming media. The speculation right now points to...
Buying Naspers in my Jubak Picks Portfolio
As I wrote in my Special Report: “10 Picks for the Emerging Markets Bounce,” (on my subscription JubakAm.com site) I’m adding Naspers (NPSNY) to my Jubak Picks Portfolio. It’s unlikely that you know much about this South African Internet...
Buying Tencent Holdings for my Jubak Picks Portfolio
Today (or tomorrow morning, actually, October 2) I’m adding Tencent Holdings (TCEHY) to my 12-18 month Jubak Picks Portfolio. (The stock is already a member of my long-term 50 Stocks Portfolio. As I wrote in my Special Report: 10 Picks for the Emerging Markets...
Oil surges on no action at OPEC meeting
Today oil prices breached levels that have oil traders talking about $100 a barrel oil again on OPEC’s decision at its weekend meeting not to boost oil production. U.S. benchmark West Texas Intermediate climbed 2.15% as of noon today, September 24, to move...
Diamondback Energy doubles down on Permian Basin
Although other oil producers in the Permian Basin look to be slowing the development of their assets in the face of transportation bottlenecks that are making it tough to get oil out of the basin, Diamondback Energy has teamed up with the Carlyle Group to form a joint...
Is the next big tech stock thing, Chinese tech stocks?
There’s some evidence that the money that has left big U.S. tech stocks such as Facebook (FB), Netflix (NFLX), Microsoft (MSFT) and Amazon (AMZN) on some recent days has been headed into big Chinese tech stocks such as Tencent Holdings (TCEHY), Alibaba (BABA),...
Do you have the patience for the Permian? Should you?
It hasn’t exactly been a great few months oil shale producers in the Permian Basin. Shares of Pioneer Natural Resources (PXD), the biggest pure play on Permian oil, closed at $169.97 a share today, August 29, down from $212.31 a share on May 18. That’s a...
Nektar beats on earnings–more importantly FDA accepts company’s new opioid for review
I wrote this post while on vacation in an effort to use this down time to catch up on earnings results that I missed during the very busy second quarter earning season. This post was written on August 18. After the market close on Wednesday, August 8,...
White House announces trade deal with Mexico to replace NAFTA
If you’re looking for a reason for U.S. stocks to keep climbing from current highs, this morning’s event at the White House is a big deal. President Donald Trump announced that the U.S. and Mexico have reached a bilateral trade agreement that would replace...
Incyte beats on revenue, misses on earnings; reports good progress in pipeline
I am on vacation until August 26. I am using that downtime to catch up on some of the earnings reports I missed during the very busy second quarter earnings season. On July 30 Incyte (INCY) reported second quarter earnings of 26 cents a share, 4 cents below the Wall...
Buying Albermarle today for my Jubak Picks Portfolio
Who says the collapse of the Turkish lira and of the Turkish stock market isn’t good news for anyone? While it’s certainly true that the troubles in Turkey–which have become worse as the country’s relationship with the United States has tipped...
Raising target price on Microsoft in Jubak Picks Portfolio after earnings
Going into yesterday’s earnings report from Microsoft, I felt torn. On the one hand, the stock had hit an all time record high on the strong guidance for the June quarter back in April. How much higher could the stock go? Would guidance for the September quarter...
Next earnings season test after Netflix? Microsoft
The Netflix (NFLX) drop yesterday (14.27%) and today (5.24%, which actually showed a recovery from the after-hours tumble) on the company’s disappointing guidance for the third quarter says that we’re still on track for a test of the earnings rally. But...Jim’s Daily Email Alerts:
Every post from Jubak Picks straight to your mailbox. And they're free!